Alterações motoras, comportamentais e histopatológicas após injeção intracerebroventricular de liquor de pacientes com esclerose lateral amiotrófica em ratos

• Autor(a) principal: Gois, Auderlan Mendonça de
• Data de Publicação: 2016
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFS
• Texto Completo: https://ri.ufs.br/handle/riufs/3988
• topic: Fisiologia; Sistema nervoso; Degeneração do sistema nervoso; Esclerose lateral amiotrófica; Líquido cefalorraquidiano; Doenças neuromusculares; Doenças neurodegenerativas; Doença do neurônio motor; Injeção intracerebroventricular; Modelo animal; Neurodegenerative diseases; Motor neuron disease; Intracerebroventricular injection; Animal model; CIENCIAS BIOLOGICAS::FISIOLOGIA

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects the somatic motor system through the degeneration of upper and lower motors neurons. Evidence suggests that the cerebrospinal fluid (CSF), which is in direct contact with the nervous system, has soluble substance that could cause injuries in motor neurons. Animal models that express mutant ALS associated genes have been created to study the various etiopathological mechanisms which manifest themselves similarly to that occur in ALS patients. However, these models best represent the etiology of the disease in familiar cases and there is not yet an animal model that represents the characteristics of the disease in sporadic form, despite the similarity between familiar and sporadic cases. Thus, the aim of this study was to evaluate the motor and histological changes after intracerebroventricular injection (i.c.v.) of CSF from ALS sporadic patients in rats. 43 seven-month-old Wistar rats were used, coming from the sectoral animal facility of the Department of Physiology at the Federal University of Sergipe. The study was divided into two experiments: (I) with a single administration i.c.v. of the CSF and (II) with repeated administration i.c.v. of the CSF. In the experiment I, the animals were divided into 3 groups: control (CTR, artificial CSF solution), non-ALS (N-ALS, CSF of patients without neurological disease) and ALS (ALS, LCR of patients with sporadic ALS) who received a single injection i.c.v. (7.5μL) and one week after were subjected to motor tests: strength test, catalepsy test, open field test and walking test once a week for 30 days. In the Experiment II, animals were divided into 3 groups: control (CTR) Non-ALS (N-ALS) and ALS and they received daily injection for 6 days, i.c.v. (5.0μL). Throughout the treatment the animals underwent the motor tests already mentioned. After the tests, in both experiments, rats were anesthetized, perfused, their spinal cords were removed and subjected to histological analysis by hematoxylin-eosin for general morphological observation. In the first experiment ,in ALS group, motor alteration was observed in the strength test, open field and in the walking test, accompanied by a reduction of motor neurons and glial cells in the thoracic and lumbar regions of the spinal cord. In the second experiment, Also in the ALS group, it was observed driving change in catalepsy, open field and in the walking test, accompanied by an increase of glial cells in the lumbar region of the spinal cord. Data presented in this study show that the CSF management of ALS patients can cause pathogenic mechanisms similar to those seen in humans and other animal models of ALS.